Liu, Yaoxing – Trademark Portfolio

Entity Type: 01

Liu, Yaoxing holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 12 (Vehicles) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include IUGZQ, OYGQA, and BELBUS. The owner is based in Hangzhou Zhejiang.

Binxing Road, Binjiang District

Rm 902, Bldg 17, Yingchun South Garden

Hangzhou Zhejiang 310051 , CN

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

IUGZQ
IUGZQ
Registered 2024
OYGQA
OYGQA
Registered 2024
BELBUS
BELBUS
Registered 2024

Trademark Classifications

Liu, Yaoxing's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

12
Vehicles (1 filing)

Vehicles; apparatus for locomotion by land, air or water

Frequently Asked Questions

How many trademarks does Liu, Yaoxing have?

Liu, Yaoxing has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does Liu, Yaoxing file in?

Liu, Yaoxing files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 12 (Vehicles). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Liu, Yaoxing's most well-known trademarks?

Liu, Yaoxing's registered trademark portfolio includes well-known marks such as IUGZQ, OYGQA, and BELBUS. These are among 3 currently registered trademarks in the portfolio.

What is Liu, Yaoxing's trademark registration success rate?

Liu, Yaoxing has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.